A5029170546- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Mesenchymal stem cell research
- Childhood Cancer Survivors' Quality of Life
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Reproductive Biology and Fertility
- Transplantation: Methods and Outcomes
- Virus-based gene therapy research
- Neutropenia and Cancer Infections
- Neonatal Respiratory Health Research
- Blood disorders and treatments
- Hepatitis B Virus Studies
- Hemoglobinopathies and Related Disorders
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- Biomedical Ethics and Regulation
- Reproductive System and Pregnancy
- Polyomavirus and related diseases
- Cancer Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Pluripotent Stem Cells Research
Centre Hospitalier Régional et Universitaire de Nancy
2016-2025
Hôpital d'Enfants
2016-2025
Ingénierie Moléculaire et Physiopathologie Articulaire
2014-2024
Centre National de la Recherche Scientifique
2020-2024
Université de Lorraine
2012-2024
Institut d’Hématologie et d’Oncologie Pédiatrique
2021
Groupe de Recherche en Énergie Électrique de Nancy
2017
Institut Gustave Roussy
2014-2016
Hôpital Debrousse
2016
Inserm
2014
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative neoplasm requiring hematopoietic stem cell transplantation (HSCT) in most cases. We retrospectively analyzed 119 JMML patients who underwent first allogeneic HSCT between 2002 and 2021. The majority (97%) carried a RAS-pathway mutation, 62% exhibited karyotypic alterations or additional mutations SETBP1, ASXL1, JAK3 and/or the RAS pathway. Relapse was primary cause of death, with 5-year cumulative incidence...
Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in treatment of hematological malignancies, is limited by life-threatening complications: graft versus host disease (GVHD) and infections especially viral refractory to antiviral drugs. Adoptive transfer virus-specific T cells becoming an alternative for following HSCT. We report here results a phase I/II multicenter study which includes series...
Abstract Background The aim of this study was to perform a description pediatric patients’ characteristics undergoing an allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and identify their cytomegalovirus (CMV) serology status that donors Methods Patients under the age 18 who received HSCT in French center reporting data ProMISe database francophone society bone marrow transplant cellular therapy (SFGM-TC) during period comprised between January 1, 2019, December 31, 2021 Results...
Minimal residual disease (MRD) is a major predictive factor of the cure rate acute lymphoblastic leukaemia (ALL). Haematopoietic cell transplantation treatment option for patients at high risk relapse. Between 2005 and 2008, we conducted prospective study evaluating feasibility efficacy reduction immunosuppressive medication shortly after non-ex vivo T depleted myeloablative transplantation. Immunoglobulin (Ig)H/T-cell receptor MRD 30 d before transplant could be obtained in 122 133 cases...
Abstract Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic cell transplantation (HCT) conditioning. The DEFIFrance post-marketing registry study evaluated effectiveness and safety in patients who received defibrotide. It collected retrospective/prospective patient data from 53 French HCT centres July 2014 to March 2020. Primary endpoints were survival complete response (CR; total serum bilirubin <2 mg/dL,...
A 1.5-year-old girl was referred to the
Summary Relapse after transplantation is a major cause of treatment failure in paediatric acute lymphoblastic leukaemia ( ALL ). Here, we report the findings prospective national study designed to investigate feasibility immune intervention children first or subsequent remission following myeloablative conditioning. This included 133 who received transplant for between 2005 and 2008. Minimal Residual Disease MRD ) based on T cell receptor/immunoglobulin gene rearrangements was measured days...
We previously reported in a French prospective randomized study that transplantation of 2 unrelated cord blood (UCB) units instead 1 unit does not decrease the risk failure but may enhance alloreactivity. Here we evaluated influence pretransplantation minimal residual disease (MRD) on leukemia relapse and survival after single- versus double-UCB (UCBT). Among 137 children young adults who underwent UCBT this study, 115 had available data MRD assessment done immediately before initiation...
Ovarian function impairment and infertility are among the most frequent late effects after hematopoietic stem cell transplantation (HSCT). The aim of this study was to evaluate ovarian function, occurrence premature insufficiency (POI), spontaneous pregnancy in a large cohort adult survivor women who had undergone HSCT for leukemia before puberty. We conducted retrospective observational from national L.E.A., long-term French follow-up program childhood leukemia. median duration 18 years...
Abstract Objective Adenovirus (AdV) infections are potentially life‐threatening for allogeneic hematopoietic stem cell transplant (allo‐ HCT ) recipients. The AdVance study aimed to evaluate the incidence, management, and outcomes of AdV in European allo‐ Methods As part study, physician surveys were conducted determine current screening treatment practices at their center. Results All 28 respondents who treat pediatric patients reported routine practices, with 93% all recipients others...
We describe herein the first reported case of a drug–drug interaction between dasatinib and esomeprazole in patient with Philadelphia-positive acute lymphoblastic leukemia leading to decrease oral absorption. The was 16-year-old man (1.76 m, 61.5 kg) who benefited from allogeneic stem cell transplantation after myeloablative conditioning regimen based on 12-Gy total body irradiation etoposide (60 mg kg–1). This is presented context progression imatinib-resistant chronic myelogenous (CML)...